

Abstract

It has been shown that Gas6 deficient endothelial cells are resistant to activation by endotoxin and TNF- α *in vitro* and *in vivo* and that leukocytes did not or much less extravasate in Gas6 deficient mice.

The present invention also relates to the manufacture of a medicament for the treatment of endothelial dysfunction. The present invention further relates to the use of an inhibitor of the Gas6 function and/or an inhibitor of a Gas6 receptor for the manufacture of said medicament.